The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Expanded GLP-1 Medication Access Through Formulary Updates
CVS Caremark's latest formulary changes are poised to strengthen GLP-1 Medication Access for commercial plan members by restoring coverage for select weight-management therapies. Effective October 1, 2026, Zepbound returns as a preferred option on template formularies for sponsors that elect c...
Integration of Comparative Effectiveness Research into Drug Pricing Frameworks
Contemporary comparative effectiveness research plays a vital role in supporting federal and state drug pricing programs by highlighting real-world benefits, yet persistent challenges and unclear guidance continue to limit its integration. Core principles of evidence evaluation, research question...
UC Biomed Building Investment: Advancing Research at the University of Coimbra
The Universidade de Coimbra (UC) is preparing to inaugurate its new UC Biomed building in the coming months, marking a significant milestone for the institution's biomedical research and teaching capabilities. According to recent updates, the facility—located at Polo III—has entered its final pha...